News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,215 Results
Type
Article (14520)
Company Profile (58)
Press Release (264636)
Multimedia
Podcasts (73)
Webinars (13)
Section
Business (101312)
Career Advice (467)
Deals (15467)
Drug Delivery (83)
Drug Development (36896)
Employer Resources (50)
FDA (6433)
Job Trends (6259)
News (151212)
Policy (14191)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (457)
Accelerated approval (26)
ADA (11)
Adcomms (9)
Allergies (100)
Alliances (23374)
ALS (74)
Alzheimer's disease (545)
Antibody-drug conjugate (ADC) (175)
Approvals (6777)
Artificial intelligence (292)
ASCO (113)
Autoimmune disease (81)
Automation (22)
Bankruptcy (152)
Best Places to Work (4383)
BIO (24)
BIOSECURE Act (9)
Biosimilars (165)
Biotechnology (28)
Bladder cancer (52)
Brain cancer (41)
Breast cancer (216)
Cancer (1811)
Cardiovascular disease (207)
Career advice (421)
Career pathing (13)
CAR-T (69)
CDC (8)
Cell therapy (207)
Cervical cancer (20)
Clinical research (32818)
Collaboration (993)
Commercialization (1)
Company closure (1)
Compensation (421)
Complete response letters (50)
COVID-19 (787)
CRISPR (55)
C-suite (689)
Cystic fibrosis (63)
Data (2660)
Decentralized trials (1)
Denatured (19)
Depression (62)
Dermatology (17)
Diabetes (171)
Diagnostics (1476)
Digital health (17)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (178)
Drug pricing (122)
Drug shortages (15)
Duchenne muscular dystrophy (107)
Earnings (34331)
Editorial (25)
Employer branding (4)
Employer resources (46)
Events (40068)
Executive appointments (635)
FDA (7920)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (2)
Frontotemporal dementia (4)
Funding (574)
Gene editing (88)
Generative AI (32)
Gene therapy (208)
GLP-1 (498)
Government (1435)
Grass and pollen (4)
Guidances (176)
Healthcare (3649)
Hematology (66)
HIV (19)
Huntington's disease (13)
IgA nephropathy (58)
Immunology and inflammation (92)
Immuno-oncology (33)
Indications (107)
Infectious disease (888)
Inflammatory bowel disease (88)
Inflation Reduction Act (7)
Influenza (29)
Intellectual property (147)
Interviews (59)
IPO (5938)
IRA (33)
Job creations (2061)
Job search strategy (374)
JPM (29)
Kidney cancer (13)
Labor market (39)
Layoffs (213)
Leadership (10)
Legal (3456)
Liver cancer (26)
Longevity (10)
Lung cancer (251)
Lymphoma (166)
Machine learning (16)
Management (17)
Manufacturing (603)
Marketing (3)
MASH (92)
Medical affairs (1)
Medical device (1317)
Medtech (1335)
Mergers & acquisitions (10081)
Metabolic disorders (579)
mRNA (65)
Multiple sclerosis (65)
NASH (15)
Neurodegenerative disease (121)
Neuropsychiatric disorders (49)
Neuroscience (1105)
Neurotech (1)
NextGen: Class of 2026 (1588)
Non-profit (610)
Now hiring (23)
Obesity (296)
Opinion (153)
Ovarian cancer (68)
Pain (140)
Pancreatic cancer (76)
Parkinson's disease (113)
Partnered (12)
Patents (297)
Patient recruitment (201)
Peanut (15)
People (30350)
Pharmaceutical (33)
Pharmacy benefit managers (19)
Phase 1 (8511)
Phase 2 (13845)
Phase 3 (12518)
Pipeline (3762)
Policy (151)
Postmarket research (1407)
Preclinical (3427)
Press Release (25)
Prostate cancer (119)
Psychedelics (24)
Radiopharmaceuticals (166)
Rare diseases (503)
Real estate (2668)
Recruiting (19)
Regulatory (11563)
Reports (16)
Research institute (582)
Resumes & cover letters (55)
Rett syndrome (12)
RNA editing (9)
RSV (25)
Schizophrenia (88)
Series A (115)
Series B (66)
Service/supplier (1)
Sickle cell disease (62)
Special edition (11)
Spinal muscular atrophy (85)
Sponsored (11)
Startups (1656)
State (2)
Stomach cancer (6)
Supply chain (66)
Tariffs (71)
The Weekly (52)
Vaccines (284)
Venture capital (41)
Weight loss (173)
Women's health (51)
Worklife (4)
Date
Today (29)
Last 7 days (152)
Last 30 days (719)
Last 365 days (10478)
2026 (5947)
2025 (10753)
2024 (12505)
2023 (14281)
2022 (19595)
2021 (20092)
2020 (19043)
2019 (14886)
2018 (11713)
2017 (13897)
2016 (13129)
2015 (15487)
2014 (12443)
2013 (10610)
2012 (11414)
2011 (11963)
2010 (10932)
Location
Africa (324)
Alabama (21)
Alaska (1)
Arizona (90)
Arkansas (4)
Asia (21339)
Australia (2752)
California (4062)
Canada (1846)
China (786)
Colorado (178)
Connecticut (161)
Delaware (172)
Europe (42157)
Florida (774)
Georgia (79)
Hawaii (1)
Idaho (11)
Illinois (473)
India (74)
Indiana (320)
Iowa (2)
Japan (364)
Kansas (85)
Kentucky (21)
Louisiana (7)
Maine (2)
Maryland (511)
Massachusetts (3286)
Michigan (55)
Minnesota (211)
Mississippi (1)
Missouri (39)
Montana (9)
Nebraska (8)
Nevada (19)
New Hampshire (9)
New Jersey (1797)
New Mexico (7)
New York (1161)
North Carolina (760)
North Dakota (2)
Northern California (1916)
Ohio (95)
Oklahoma (5)
Oregon (16)
Pennsylvania (878)
Puerto Rico (18)
Rhode Island (18)
South America (509)
South Carolina (12)
Southern California (1810)
Tennessee (74)
Texas (570)
United States (16062)
Utah (67)
Vermont (1)
Virginia (209)
Washington D.C. (42)
Washington State (297)
West Virginia (1)
Wisconsin (55)
Wyoming (1)
279,215 Results for "aprecia pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Aprecia and Battelle Are Impacting The Pharmaceutical Industry Through 3D Printing Innovation
Aprecia, a precision drug delivery company, has partnered with the research and development experts at Battelle to develop groundbreaking 3D printing platforms with the potential to transform the way medicines are developed, manufactured, distributed, and administered.
November 15, 2023
·
4 min read
Press Releases
Battelle and Aprecia Collaborate with U.S. Department of Health and Human Services (HHS) and U.S. Defense Advanced Research Projects Agency (DARPA) to Advance U.S. Drug Manufacturing Capability Utilizing 3D-Printed Technology to Produce Essential Medicines at the Point of Need
August 20, 2025
·
5 min read
Business
Aprecia Names Industry Leader Owen Murray as Its CEO
Aprecia Pharmaceuticals today announced Owen Murray as its Chief Executive Officer.
January 30, 2023
·
2 min read
BioMidwest
Glatt Pharmaceutical Services and Aprecia to Advance Patient Focused Pharmaceuticals with Aprecia’s 3D-Printing Technology
Glatt Pharmaceutical Services and Aprecia announce their joint effort to accelerate and expand the use of Glatt’s multiparticulate technologies through Aprecia’s 3DP manufacturing
February 23, 2021
·
3 min read
Business
Aprecia Selects Garry Hedgepeth to Lead Quality Team
Aprecia Pharmaceuticals announced that it has hired Garry Hedgepeth as Vice President of Quality.
March 8, 2022
·
2 min read
Press Releases
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetings
June 18, 2026
·
5 min read
Press Releases
Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals
July 16, 2026
·
9 min read
Press Releases
GNI Group Completes Acquisition of AYUMI Pharmaceutical
July 1, 2026
·
5 min read
Press Releases
Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio
June 28, 2026
·
5 min read
Press Releases
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora’s ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa
June 18, 2026
·
4 min read
1 of 27,922
Next
